Topical vascular endothelial growth factor reverses delayed wound healing secondary to angiogenesis inhibitor administration

Wound Repair and Regeneration

Volumn 13, Issue 5, 2005, Pages 506-512

  Michaels V, Joseph ^a   Dobryansky, Michael ^a   Galiano, Robert D ^a   Bhatt, Kirit A ^a   Ashinoff, Russell ^a   Ceradini, Daniel J ^a   Gurtner, Geoffrey C ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; ENDOSTATIN; PHOSPHATE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EPITHELIUM; EPITHELIZATION; GRANULATION TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULARIZATION; WOUND CLOSURE; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ENDOSTATINS; GRANULATION TISSUE; GROWTH SUBSTANCES; MICE; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 28944447082     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1067-1927.2005.00071.x     Document Type: Article

References (24)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-7.
3. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8.
4. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
5. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
6. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9.
7. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995;92:7799-803.
8. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
9. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-9.
10. Yu Y, Moulton KS, Khan MK, Vineberg S, Boye E, Davis VM, O'Donnell PE, Bischoff J, Milstone DS. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci USA 2004;101:8005-10.
11. Folkman J, Shing Y, Angiogenesis. J Biol Chem 1992;267: 10931-4.
12. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-70.
13. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738-46.
14. Klein SA, Bond SJ, Gupta SC, Yacoub OA, Anderson GL. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 1999;82:268-74.
15. Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, Figg WD, Alexander HR, Libutti SK. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 2000;91:26-31.
16. Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, Timpl R, Werner S. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000;14:2373-6.
17. Lange-Asschenfeldt B, Velasco P, Streit M, Hawighorst T, Pike SE, Tosato G, Detmar M. The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. J Invest Dermatol 2001;117:1036-41.
18. Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, Beauchamp RD. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43-7.
19. Dobryansky M, Galiano RD, Cetrulo CL Jr, Bhatt KA, Michaels J, Ashinoff R, Levine JP, Gurtner GC. Endostatin inhibits ischemia-induced neovascularization and increases ischemic tissue loss. Ann Plast Surg 2004;52:512-8; discussion 518.
20. Galiano RD, Michaels J, Dobryansky M, Levine JP, Gurtner GC. A quantitative and reproducible murine model of excisional wound healing. Wound Rep Reg 2004;12:485-92.
21. Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski JE, Fortier AH. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999;3:41-51.
22. Ann ST, Mustoe TA. Effects of ischemia on ulcer wound healing: a new model in the rabbit ear. Ann Plast Surg 1990;24:17-23.
23. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-803.
24. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, Bunting S, Steinmetz HG, Gurtner GC. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004;164:1935-47.